Jianshin Superconductor's sci-tech innovation board IPO was approved at the listing committee meeting, and in 2024, the company ranked fifth among global superconducting magnet manufacturers.

On October 21st, Ningbo Jiangxin Superconductive Technology Co., Ltd. (referred to as Jiangxin Superconductive) passed the meeting of the Sci-Tech Innovation Board Listing Committee of the Shanghai Stock Exchange. GF SEC is its sponsor and plans to raise 775 million yuan. According to data from Zhushi Consultancy, based on installed capacity statistics, Jiangxin Superconductive ranks fifth among global superconducting magnet manufacturers in 2024, with a global market share of approximately 4.2%. The prospectus shows that Jiangxin Superconductive mainly engages in the research, development, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets, permanent magnets, and gradient coils. In the superconducting field, the company has developed a rich product portfolio including 1.5T zero boil-off superconducting magnets, 1.5T helium-free superconducting magnets, 3.0T zero boil-off superconducting magnets, and open zero boil-off superconducting magnets, becoming the leading independent supplier of superconducting magnets in the global MRI industry. In the permanent magnet field, the company utilizes high-performance magnetic materials and efficient magnetic circuit design, and introduces design technologies such as low eddy current and high openness to provide customers with a wide range of high-quality permanent magnets. It is currently the largest global supplier of permanent magnets for MRI equipment. As a leading professional supplier of core components for magnetic resonance imaging worldwide, Jiangxin Superconductive has established close cooperation with well-known MRI equipment manufacturers at home and abroad such as Fujifilm Group in Japan, GE Healthcare in the United States, Bracco in Italy, Beijing Wandong Medical Technology, Shenzhen Angke, Shanghai United Imaging Healthcare, and Fochon Medical. Through overseas subsidiaries and the innovation of the MRI equipment supply chain model through patent technology research and development, the company significantly reduces the final delivery cost. Over 50% of the company's products are sold to Japan, Europe, the United States, and other emerging markets overseas, promoting the global popularity of MRI equipment. The funds raised this time will be invested in the annual production of 600 sets of helium-free superconducting magnet projects, the annual production of 600 sets of high-field strength medical superconducting magnet technical transformation projects, and new superconducting magnet research and development projects. The funds raised will focus on the company's main business, concentrate on national strategies and major needs, increase research and development innovation investment, further improve the industrial chain and product structure, and enhance the competitiveness of the company's products and technology. Financially, in the fiscal years 2022, 2023, 2024, and January-June 2025, the company's main business income was 332 million yuan, 422 million yuan, 401 million yuan, and 238 million yuan respectively. In 2024, the company's main business income slightly decreased compared to 2023, due to a decrease in revenue from permanent magnet products affected by the decline in raw material prices of magnetic steel, and a slowdown in the growth rate of superconductor product revenue due to the overall pressure on the domestic medical procurement market and the pace of implementation of medical equipment update policies.